Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: uniQure N.V., 3 years.
uniQure N.V.
Director
CG Oncology Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 15, 2026 | CG Oncology Inc. | Option exercise | +1,000 | $0.60 | $600 |
| Oct 15, 2026 | CG Oncology Inc. | Open-market sale | −500 | $61.65 | $30,825 |
| Oct 15, 2026 | CG Oncology Inc. | Open-market sale | −500 | $62.48 | $31,240 |
| Sep 15, 2026 | CG Oncology Inc. | Option exercise | +1,000 | $0.60 | $600 |
| Sep 15, 2026 | CG Oncology Inc. | Open-market sale | −1,000 | $72.98 | $72,980 |
| Aug 14, 2026 | CG Oncology Inc. | Option exercise | +1,000 | $0.60 | $600 |
| Aug 14, 2026 | CG Oncology Inc. | Open-market sale | −1,000 | $74.54 | $74,540 |
| Jul 15, 2026 | CG Oncology Inc. | Option exercise | +1,000 | $0.60 | $600 |
| Jul 15, 2026 | CG Oncology Inc. | Open-market sale | −1,000 | $71.17 | $71,170 |
| Jun 24, 2026 | CG Oncology Inc. | Option exercise | +5,000 | $0.60 | $3,000 |
| Jun 24, 2026 | CG Oncology Inc. | Open-market sale | −5,000 | $70.00 | $350,000 |
| Jun 22, 2026 | CG Oncology Inc. | Option exercise | +5,000 | $0.60 | $3,000 |
| Jun 22, 2026 | CG Oncology Inc. | Open-market sale | −5,000 | $65.00 | $325,000 |
| Jun 11, 2026 | uniQure N.V. | Open-market sale | −1,993 | $27.06 | $53,931 |
| Jun 10, 2026 | uniQure N.V. | Grant or award | +7,550 | — | — |
Questions about Leonard E. Post
What boards is Leonard E. Post on?
Leonard E. Post sits on the boards of CG Oncology Inc. and uniQure N.V.
How long has Leonard E. Post served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.